Corcept Therapeutics Incorporated
NASDAQ:CORTBiotechnology
-$1.96 today
- Market cap
- $7.42B
- Beta
- 0.50
- P/E (TTM)
- 178.2
- EPS (TTM)
- $0.46
Volume 0.74M
Average 1.41M
CORT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Corcept Therapeutics IncorporatedNASDAQ: CORT
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 8.1% from a year ago
Cash & equivalents stood at $111.04M at the end of Q2 FY2026, up 8.1% from a year earlier and up 2.1% from the prior quarter. Over 3 fiscal years it compounded at +22.0% a year.
Context
- Cash & equivalents amounted to 12.5% of total assets at the end of Q2 FY2026, down 0.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +8.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 120.5M USD
- Year-over-year change
- -5.6%
- 4-year CAGR
- +11.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120.5M | -5.6% |
| FY2024 | 2024-12-31 | 127.67M | -5.8% |
| FY2023 | 2023-12-31 | 135.55M | +104.4% |
| FY2022 | 2022-12-31 | 66.33M | -14.5% |
| FY2021 | 2021-12-31 | 77.62M | — |
Cash & Equivalents vs competitors
How CORT compares with its peers on the latest reported figures
- CORT's Jun 2026 cash & equivalents of $111.04M is the 2nd highest of the 3 companies compared; the peer median is $107.89M.
- Its year-over-year change of +8.1% is the 2nd highest of 3, against a peer median of +41.8%.
- Cash & equivalents amounts to 12.5% of total assets for CORT, versus a peer median of 64.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $161.69M | -27.5% | +46.0% | 32.3% |
| Jun 2026 | $111.04M | +8.1% | +22.0% | 12.5% | |
| Mar 2026 | $54.08M | +111.1% | +25.9% | 96.3% | |
| Peer median (excluding CORT) | $107.89M | +41.8% | +35.9% | 64.3% | |
Competitors are the stored peer set for CORT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77.62M | 66.33M | 135.55M | 127.67M | 120.5M |
| Short-term Investments | 145.92M | 365.34M | 232.67M | 255.67M | 251.66M |
| Net Receivables | 29.03M | 46.86M | 56.82M | 58.08M | 59.79M |
| Inventory | 4.99M | 6.1M | 7.73M | 12.41M | 12.87M |
| Other Current Assets | 8.92M | 14.62M | 25.86M | 8.29M | 12.16M |
| Total Current Assets | 266.46M | 499.25M | 458.64M | 471.6M | 485.46M |
| Property, Plant & Equipment (Net) | 1.52M | 1.78M | 315K | 8.01M | 6.47M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 112.28M | 4.95M | 57.18M | 219.83M | 160.27M |
| Tax Assets | 27.46M | 61.47M | 90.61M | 130.91M | 168.2M |
| Other Non-current Assets | 16.05M | 15.99M | 14.79M | 10.19M | 16.25M |
| Total Non-current Assets | 157.29M | 84.18M | 162.88M | 368.95M | 351.19M |
| Total Assets | 423.76M | 583.43M | 621.52M | 840.55M | 836.65M |
| Account Payables | 6.91M | 11.98M | 17.4M | 15.38M | 40.44M |
| Short-term Debt | 526K | 1.14M | 151K | 829K | 0 |
| Tax Payables | 513K | 89K | 2.89M | 191K | 15.18M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 35.68M |
| Other Current Liabilities | 26.26M | 43.77M | 59.69M | 82.65M | 44.31M |
| Total Current Liabilities | 47.54M | 72.49M | 104.51M | 140.77M | 166.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 5.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 409K | 9.1M | 10.31M | 14.08M | 17.74M |
| Total Non-current Liabilities | 409K | 9.1M | 10.31M | 20.19M | 22.76M |
| Total Liabilities | 47.95M | 81.59M | 114.81M | 160.96M | 188.85M |
| Common Stock | 127K | 131K | 133K | 136K | 140K |
| Retained Earnings | 194.97M | 296.39M | 402.53M | 543.74M | 643.39M |
| Accumulated OCI | (227K) | (869K) | 609K | (217K) | 2.26M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 375.81M | 501.84M | 506.71M | 679.59M | 647.81M |
| Total Debt | 526K | 1.14M | 151K | 6.94M | 6.11M |
| Net Debt | (77.09M) | (65.19M) | (135.4M) | (120.73M) | (114.39M) |
Corcept Therapeutics Incorporated
NASDAQ:CORT
Intrinsic Alpha fair value
Locked
Current Price
$67.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.